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Sweet syndrome (SS), or acute febrile neutrophilic derma-
tosis, is a rare inflammatory disorder characterized by
painful cutaneous nodules and neutrophilic infiltrate in the
dermis without vasculitis. Malignancy-associated SS (MASS)
comprises 15e20% of SS cases, in which acute myeloid
leukemia (AML) is the most commonly related malignancy.1
We report a case of a 15-year-old girl with AML who initially
had MASS as a paraneoplastic syndrome.
2. Case Report
A 15-year-old obese (weight: 101 kg, height: 162 cm) girl was
admitted to our hospital with a 3-day history of fever up to
39C, malaise, arthralgia, and painful erythematous nodules
sized from 1 1 cm to 3 3 cm over bilateral feet and calves
(Figure 1A). She had a history of congenital hydrocephalus,* Corresponding author. College of Medical Science and Tech-
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ital syndrome. Her hemogram revealed a white blood cell
(WBC) count of 5.3 109/L (segmented neutrophils 23%,
lymphocytes 45%, and monocytes 32%), hemoglobin of 8.9 g/
dL, and platelets of 106 109/L. Her C-reactive protein level
was 14.5 mg/dL, and erythrocyte sedimentation rates were
140 mm/h and>140 mm/2 h.
The initial diagnosis was severe cellulitis. A skin lesion
culture and blood culture yielded no bacterial growth. Due
to the poor response to empiric antibiotic treatment with
vancomycin and ceftriaxone, hypersensitive vasculitis was
suspected and levofloxacin and an antihistamine were
administered, to which the skin lesions showed a partial
response. A skin biopsy revealed dense neutrophilic infil-
tration in the dermis and subcutaneous fat without vascu-
litis (Figure 1B). A diagnosis of SS was made.
Ten days after biopsy, the girl had recurrent fever and her
WBC count increased to 14.1 109/L with blasts comprising
39%. A bonemarrow aspiration revealed hypercellularmarrow
with intensive infiltration of myeloblasts (>90%). Flow
cytometry was positive for CD13 and CD33. Further molecular
studies revealed normal cytogenetics with FLT3 internalemia Presenting with Sweet Syndrome: A Case Report and Review
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Figure 1 Clinicopathological features of Sweet syndrome in our patient: (A) nodular skin lesions localized at the lower left foot;
(B) skin biopsy showed neutrophilic infiltration (arrows) of the subcutaneous adipose tissue and dermis (hematoxylin and eosin
stain, 200; inlet, 400).
+ MODELtandem duplication (by reverse transcriptase polymerase
chain reaction) and NPM1 type A mutation (by direct
sequencing).
Following standard induction chemotherapy with cytosine
arabinoside 100 mg/m2/d for 7 days and idarubicin 9 mg/m2/
d for 3 days, the skin lesions completely resolved. The girl had
transient remission in her peripheral blood with platelet recov-
ery and underwent a second cycle of induction chemotherapy.
3. Discussion
SSwas originally describedbyDrRobertD. Sweet in 1964,when
he reported on eight middle-aged women who manifested py-
rexia, painful erythematousplaques,neutrophilia, andadense
dermal infiltration with mature neutrophils.2 SS responds
rapidly to systemic corticosteroids. The diagnosis of SS should
fulfill two major and two minor criteria.3,4 Major criteria
include: (1) abrupt onset of tender erythematous papules or
nodules; and (2) predominant neutrophilic infiltrate in the
dermis without leukocytoclastic vasculitis. Minor criteria
include: (1) presence of fever  38C; (2) at least two of four
abnormal laboratory values (WBC > 8 109/L, neutrophil >
70%, erythrocyte sedimentation rates > 20 mm/h, and abnor-
mally elevated C-reactive protein); (3) a disease/condition
associated with SS (e.g., malignancy, inflammatory disorder,
pregnancy, etc.); and (4) excellent response to glucocorticoid
therapy or potassium iodide.4 Our patient met two major
criteria and two minor criteria (fever and malignancy).
The pathogenesis of SS, although not yet clear, may be
hypersensitivity to an underlying infectious, inflammatory,
or malignant condition that stimulates the production of
cytokines, including granulocyte colony-stimulating factor.
As a result, neutrophils are activated and they abnormally
migrate into dermal tissues.
Hematologic disorders account for more than 85% of MASS
cases. AML and myelodysplastic syndrome are the most com-
mon.5Kazmietal6reportedthatSSoccursin1%(21/2178)ofadult
AML patients: two-thirds were women and only one out of 21
patients with SS had presented prior to the diagnosis of AML,
similar to our patient. Risk factors for MASS in AML includePlease cite this article in press as: Chen S-H, et al., Acute Myeloid Leu
of the Literature, Pediatrics and Neonatology (2016), http://dx.doi.odeletionofchromosome5or5q,presenceofFLT3mutations,and
AMLwith myelodysplasia-related features. Themedian overall
survival for AML patients with SS was not significantly different
fromtherestoftheAMLpatientswithoutSS.Consistentwiththe
common features reported by Kazmi et al,6 our case was a girl
who had a FLT3 mutation, thrombocytopenia, and anemia.
Levofloxacinwasreportedtohaveananti-inflammatoryeffectin
an animal study.7 This may have contributed to the initial
improvement of our patient’s skin condition.
In conclusion, SS is rare, it mimics infection, but can be
an early sign of a malignancy. Although systemic cortico-
steroids are the first-line treatment of SS, administration of
steroids can be harmful and may obscure the diagnosis of
leukemia. When a child has typical skin lesions of SS, the
pediatrician should keep a high index of suspicion to search
for underlying malignancies and systemic disorders.
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